2. Signaling Pathways
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CCR

CCR

CC chemokine receptor

CCR

Related Products

PDF 0.04 MB

CCR (Chemokine receptors) are cytokine receptors found on the surface of certain cells that interact with a type of cytokine called achemokine. There have been 19 distinct chemokine receptors described in mammals. Each has a 7-transmembrane (7TM) structure and couples to G-protein for signal transduction within a cell, making them members of a large protein family of G protein-coupled receptors. Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca2+) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism. Chemokine receptors are divided into different families, CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct subfamilies of chemokines they bind. Specific chemokine receptors provide the portals for HIV to get into cells, and others contribute to inflammatory diseases and cancer.

CCR Isoform Specific Products:

CCR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-19974
    TAK-220
    		Antagonist 99.95%
    TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.
    TAK-220
  • HY-112792
    CCR2 antagonist 1
    		Antagonist 98.00%
    CCR2 antagonist 1 (compound 15a) is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM.
    CCR2 antagonist 1
  • HY-135891
    AZD2423
    		Antagonist 99.91%
    AZD2423 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator. AZD2423 has an IC50 of 1.2 nM for CCR2 Ca2+ flux .
    AZD2423
  • HY-P3418
    CKLF1-C27
    		Inhibitor 98.46%
    CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research.
    CKLF1-C27
  • HY-U00350
    CCX354
    		Antagonist 99.18%
    CCX354 is an antagonist of CCR1, with anti-inflammatory activity.
    CCX354
  • HY-157453
    CCR4 antagonist 4
    		Antagonist 99.72%
    CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC50 of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC50: 0.007 μM) and Ca2+ mobilization (IC50: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research.
    CCR4 antagonist 4
  • HY-153670
    IPG7236
    		Antagonist 98.54%
    IPG7236 is a selective and orally active CC chemokine receptor 8 (CCR8) antagonist with an IC50 of 24 nM in a Tango assay. IPG7236 effectively inhibits the downstream signaling of CCR8 induced by CCL1 (IC50 = 8.44 nM), CCL1-induced downstream signaling in the CCR8-overexpressing cells (IC50 = 24.3 nM), and CCL1-induced CCR8+ Treg cells’ migration (IC50 = 33.8 nM) .IPG7236 demonstrates an anti-cancer effect via up-regulating Treg and down-regulating cytotoxic T (CD8+ T) cells. IPG7236 can used for the study of breast cancer.
    IPG7236
  • HY-103355
    YM022
    		Antagonist 99.87%
    YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo.
    YM022
  • HY-144200
    CCR8 antagonist 2
    		Antagonist 98.34%
    CCR8 antagonist 2 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220).
    CCR8 antagonist 2
  • HY-156460
    CMKLR1 antagonist 1
    		Antagonist 99.44%
    CMKLR1 antagonist 1 (compound S-26d) is a potent and orally active chemokine-like receptor 1 (CMKLR1) antagonist, with a pIC50 value of 7.44 in hCMKLR1-transfected CHO cells. CMKLR1 antagonist 1 can be used for psoriasis and metabolic diseases research.
    CMKLR1 antagonist 1
  • HY-17377
    Vicriviroc maleate
    		Antagonist 99.91%
    Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570).
    Vicriviroc maleate
  • HY-P3982
    CKLF1-C19
    		Chemical 99.76%
    CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4.
    CKLF1-C19
  • HY-15546
    BMS-817399
    		Antagonist 99.83%
    BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis.
    BMS-817399
  • HY-U00331
    CCR3 antagonist 1
    		Antagonist 98.95%
    CCR3 antagonist 1 is a potent antagonist of CCR3, used for the research of immunologic and inflammatory diseases.
    CCR3 antagonist 1
  • HY-124759
    CCR1 antagonist 9
    		Antagonist 99.65%
    CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC50 of 6.8 nM in calcium flux assay.
    CCR1 antagonist 9
  • HY-120588
    BI 639667
    		Antagonist 99.47%
    BI 639667 (compound 19n), a chemical probe, is a CCR1 antagonist, with an IC50 of 1.8 nM in Ca2+ flux assay.
    BI 639667
  • HY-123763
    MLN3126
    		Antagonist 98.02%
    MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx.
    MLN3126
  • HY-B0673S
    Pirfenidone-d5
    		Inhibitor 98.88%
    Pirfenidone-d5 is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
    Pirfenidone-d<sub>5</sub>
  • HY-148100A
    Emapticap pegol sodium
    		Inhibitor
    Emapticap pegol sodium is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol sodium is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36).
    Emapticap pegol sodium
  • HY-P4191A
    Met-RANTES (human) acetate
    		Antagonist 99.62%
    Met-RANTES (human) acetate is the acetate form of Met-RANTES (human) (HY-P4191). Met-RANTES (human) acetate is the antagonist for CCR1 and CCR5. Met-RANTES (human) acetate inhibits chemokines human MIP-1α and MIP-1β with IC50 of 5 and 2 nM. Met-RANTES (human) acetate reduces bone destruction and ameliorates rats adjuvant-induced arthritis (AIA).
    Met-RANTES (human) acetate
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CCR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.